Home > Formulary : Adult > Recent Decisions > 2019 >
Decisions 15th January 2019
At the meeting on the 15th January the following decisions were agreed:
New Drug Requests
Approved
Budesonide orodispersible tablets
- Approved for treatment of eosinophilic esophagitis
Salofalk®
- Approved for treatment of mild to moderate ulcerative colitis
Duloxetine
- Approved for treatment resistant neuropathic pain as per BNSSG neuropathic pain guidelines
Taptiqom® eye drops
- Approved for the reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension
Further work needed
Lidocaine plasters
- The group agreed that further work was needed before lidocaine plasters could be added to the formulary.
Not Approved
Softacort® eye drops
- Not approved for treatment of mild non-infectious allergic or inflammatory conjunctival diseases.
Shared Care Protocols/TLS change in status
Brivaracetam SCP
- New SCP approved
Insulin degludec (TLS amber 3 months to amber no SCP)
- The group agreed to change in TLS from amber 3 months to amber no SCP
Azathioprine SCP
- New SCP approved for azathioprine for the management of autoimmune hepatitis
Tadalafil (TLS amber to blue)
- The group agreed to change in TLS from amber to blue
Other
- Adalimumab biosimilars; Imraldi®, Amgevita® to be added
- Insulin glargine biosimilars; Semglee® to be added